Coya Therapeutics

DelveInsight's Exosomes Pipeline Insight 2024 report details 75+ therapies from 70+ companies, including Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, and others. Key therapies like ExoCoVac, COYA 201, EV-101, and StemXO are in various clinical trial phases. Notable approvals include Aruna Bio's AB126 for acute ischemic stroke and EXO Biologics' EXOB-001 for bronchopulmonary dysplasia. The report covers mechanism of action, route of administration, and market dynamics.

Coya Therapeutics' CEO Howard Berman and incoming CEO Arun Swaminathan will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Oct 1, 2024. The company develops biologics enhancing regulatory T cell function to target systemic and neuroinflammation, with a lead product COYA 302 for neurodegenerative diseases.

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

The ALS drug development pipeline is rich with promising therapies targeting TDP-43 pathology, including Biogen’s BIIB-105, AbbVie/Calico’s ABBV-CLS-7262, Denali’s DNL-343, and QurAlis’ QRL-201. Trials range from Phase 1 to Phase 3, with completion dates extending to 2026. These therapies aim to slow ALS progression by addressing TDP-43 mislocalization and aggregation, a hallmark of ALS pathology. The article also highlights the importance of clinical trials in advancing ALS treatment and the potential for FDA approval of these therapies.